Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Expert Opin Drug Saf ; 13 Suppl 1: S21-9, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25171156

ABSTRACT

OBJECTIVE: Adverse drug reaction (ADR) reporting by patients has a fundamental role in pharmacovigilance. The main objectives of the present study were to assess the impact of a pharmacist-based intervention in promoting direct patient reporting, to evaluate patient ability to identify and report ADRs and to determine their pattern. RESEARCH DESIGN AND METHODS: The study involved 96 pharmacists in the Campania region of Italy, who interviewed their customers and asked them whether they had experienced an ADR. Patients who had experienced an ADR were invited to complete an ADR reporting form. The quality of completed ADR reporting forms was evaluated before their entry into the Italian Spontaneous Reporting System (Rete Nazionale di Farmacovigilanza [RNF]) and, once entered, their pattern was determined. RESULTS: A total of 18,677 patients were interviewed, and 10.88% had experienced an ADR. After quality control, 54.32% of all reporting forms were entered into the RNF so that patient contribution to spontaneous reporting, null over the years, reached ∼7%. Patients reported mainly non-serious (91.28%) and expected (94.62%) ADRs, and NSAIDs or antibiotics were the most frequently reported drugs. CONCLUSIONS: The study shows that pharmacists can have an important role in promoting patient reporting and adds new information on how a patient reporting form should be structured.


Subject(s)
Adverse Drug Reaction Reporting Systems/statistics & numerical data , Community Pharmacy Services/organization & administration , Drug-Related Side Effects and Adverse Reactions/epidemiology , Pharmacists/organization & administration , Adolescent , Adult , Aged , Female , Humans , Italy/epidemiology , Male , Middle Aged , Pharmacovigilance , Professional Role , Self Report , Young Adult
2.
Expert Opin Drug Saf ; 13 Suppl 1: S31-40, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25171157

ABSTRACT

OBJECTIVE: Although bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) is well recognized, little is known about it in terms of pathophysiology, epidemiology or management. We analyzed all suspected BRONJ reports sent to the Italian Pharmacovigilance Adverse Event Spontaneous Reporting System (Rete Nazionale Farmacovigilanza [RNF]) to determine their pattern and add new information about this relevant issue. RESEARCH DESIGN AND METHODS: All suspected BRONJ sent to the RNF between 2003 and 2011 were retrieved. After a case-by-case assessment procedure, we analyzed BP type, BP exposure time and time since last use. RESULTS: Between 2003 and 2011, 555 reports of osteonecrosis of the jaw (ONJ) after BP administration were recorded in the RNF. These events occurred mostly in patients affected by cancer (77.84%) in which zoledronate was the most frequently suspected BP. Most patients experienced ONJ after long-term use of the drug (median time of BP exposure being between 1.3 and 8.8 years). Interestingly, 139 (25.05%) cases of ONJ occurred between 2 and 121 months after BP withdrawal. CONCLUSION: This study shows that BRONJ can occur much earlier than hitherto reported, adds new data on BRONJ onset following ibandronate treatment and reveals that patients who cease BP-based therapy develop ONJ, raising the question of post-treatment monitoring strategies.


Subject(s)
Adverse Drug Reaction Reporting Systems/statistics & numerical data , Bisphosphonate-Associated Osteonecrosis of the Jaw/epidemiology , Diphosphonates/adverse effects , Aged , Aged, 80 and over , Bisphosphonate-Associated Osteonecrosis of the Jaw/etiology , Bone Density Conservation Agents/administration & dosage , Bone Density Conservation Agents/adverse effects , Diphosphonates/administration & dosage , Female , Humans , Italy/epidemiology , Male , Middle Aged , Product Surveillance, Postmarketing , Time Factors
3.
Eur J Clin Pharmacol ; 70(2): 187-95, 2014 Feb.
Article in English | MEDLINE | ID: mdl-24145814

ABSTRACT

PURPOSE: To evaluate the effect of a broad range of covariates on the survival of a real-life long-term follow-up cohort of community-dwelling patients with behavioural and psychological symptoms of dementia who were new users of atypical antipsychotic medications (APMs). METHODS: This was a prospective cohort study of 1,618 subjects aged ≥65 years with dementia and BPSD ("behavioural and psychological symptoms of dementia") who were new users of atypical APMs and registered in a Dementia Evaluation Unit of Campania Region (Italy) from September 2006 to March 2010. The potential of baseline features to predict mortality was assessed with the Cox proportional hazards model. RESULTS: The average follow-up was 309 days. Of the 1,618 new users of atypical antipsychotics, 9.3 % experienced at least one adverse event, including death (5.1 %), drug therapeutic failure (3.0 %), extrapyramidal symptoms (0.5 %) and stroke (0.2 %). The crude all-cause mortality rate was 6.0 per 100 person-years [95 % confidence interval (CI) 4.8-7.4]; the rate was higher in patients aged >85 years (9.0 per 100 person-years, 95 % CI 6.4-12.7) and among male patients (7.5 per 100 person-years, 95% CI 5.3-10.6). In the multivariate analysis, only age was associated to all-cause mortality [hazard ratio (HR) 1.1; 95 % CI 1.0-1.1 and HR 1.4; 95 % CI: 0.9-2.2, respectively). In contrast, hallucination (HR 0.4; 95 % CI 0.2-0.6) and dosage change (HR 0.4; 95 % CI 0.2-0.78) were significantly associated with a lower risk of all-cause mortality. CONCLUSIONS: Among our patient cohort, the mortality rate of patients with BPSD receiving long-term treatment with atypical APMs was lower than that reported in other studies, and only age was found to be significant predictor factor of mortality.


Subject(s)
Antipsychotic Agents/therapeutic use , Dementia/mortality , Aged , Aged, 80 and over , Antipsychotic Agents/adverse effects , Cohort Studies , Dementia/psychology , Female , Humans , Independent Living , Italy/epidemiology , Male , Pharmacovigilance
4.
PLoS One ; 8(7): e69954, 2013.
Article in English | MEDLINE | ID: mdl-23922868

ABSTRACT

Moderate exercise training improves energetic metabolism, tissue perfusion and induces cardiac and skeletal muscle remodeling. Sildenafil, a potent phosphodiesterase-5 inhibitor used to treat erectile dysfunction, reduces infarct size and increases tissue oxygenation in experimental models of cardiovascular disease. We have evaluated the effects of prolonged moderate exercise training and a repeat administration of sildenafil on the rat gastrocnemius and cardiac muscles. Animals were divided into two groups: sedentary and trained. Each group was subdivided into animals treated with vehicle or with two doses of sildenafil (10 or 15 mg/kg/day) during the last week of training. Physical exercise did not induce cardiac hypertrophy, whereas it increased mRNA levels of the PGC-1α, HIF-1α and VEGF genes, which are involved in mitochondrial biogenesis and angiogenesis, and reduced mRNA levels of FoxO3a, MuRF-1 and Atrogin-1. Sildenafil dose-dependently promoted both angiogenesis, as shown by increased capillary density, and muscle atrophy, as shown by muscle fibre size. These effects were more pronounced in trained animals. Our data confirm the beneficial effects of a moderate and prolonged training on cardiovascular and skeletal systems and document the positive and negative effects of sildenafil on these tissues at doses higher than those used in clinical practice. This report may impact on the use of sildenafil as a substance able to influence sports performance.


Subject(s)
Muscle, Skeletal/drug effects , Physical Conditioning, Animal/physiology , Piperazines/pharmacology , Sulfones/pharmacology , Animals , Blotting, Western , Forkhead Box Protein O3 , Forkhead Transcription Factors/genetics , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Male , Mitochondria, Muscle/metabolism , Muscle Proteins/genetics , Myocardium/metabolism , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha , Purines/pharmacology , Rats , Rats, Wistar , Reverse Transcriptase Polymerase Chain Reaction , Sildenafil Citrate , Transcription Factors/genetics , Tripartite Motif Proteins , Ubiquitin-Protein Ligases/genetics , Vascular Endothelial Growth Factor A/genetics
5.
J Child Adolesc Psychopharmacol ; 22(6): 415-22, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23234585

ABSTRACT

OBJECTIVE: Our intensive pharmacosurveillance monitoring program was performed to increase the number of adverse drug reactions (ADRs) recorded in the Italian spontaneous reporting database, and to systematically collect more thorough data about atomoxetine (ATX) and methylphenidate (MPH) safety in the pediatric setting. METHODS: From September 2007 to October 2010, 1841 youth were enrolled in the Italian Attention- Deficit/Hyperactivity Disorder Register, but we report here on the 76 children from the five Reference Prescription Centers in Campania, an Italian region where we administered our systematic adverse event checklist. RESULTS: Among our cohort, 68 children received a prescription of ATX and 8 received a prescription of MPH. Most children were male and between 10 and 13 years of age, had a diagnosis of attention-deficit/hyperactivity disorder-combined (ADHD-C) and had learning disability as the main comorbidity. Most ADRs reported to the Italian spontaneous reporting database occurred in patients from Campania. Twenty-five experienced at least 1 ADR for a total of 40 ADRs reported to the Italian drug agency. Most ADRs were common and not serious, and resolved completely. Weight loss was the most frequently reported ADR. Only two ADRs were unexpected and only one was uncommon. Sixteen ADRs resulted in permanent drug withdrawal. Based on the Naranjo algorithm, 25 ADRs were considered "probable" and 15 were considered "possible." CONCLUSIONS: Although our data provide reassurance of the safety of ATX and MPH, several unexpected or uncommon ADRs (hepatomegaly, suicidal ideation, weight gain, or drug interactions) were identified by our intensive pharmacosurveillance monitoring program. Our results show that an intensive pharmacosurveillance monitoring program that involves pharmacovigilance centers and clinicians can improve the collection of information on drug safety in children.


Subject(s)
Attention Deficit Disorder with Hyperactivity/drug therapy , Methylphenidate/adverse effects , Propylamines/adverse effects , Adolescent , Adrenergic Uptake Inhibitors/adverse effects , Adrenergic Uptake Inhibitors/therapeutic use , Adverse Drug Reaction Reporting Systems/statistics & numerical data , Atomoxetine Hydrochloride , Central Nervous System Stimulants/adverse effects , Central Nervous System Stimulants/therapeutic use , Child , Databases, Factual , Female , Humans , Italy , Male , Methylphenidate/therapeutic use , Pharmacovigilance , Propylamines/therapeutic use , Registries
6.
Eur J Immunol ; 42(5): 1129-39, 2012 May.
Article in English | MEDLINE | ID: mdl-22539288

ABSTRACT

CD127 is the IL-7 receptor α-chain and its expression is tightly regulated during T-cell differentiation. We previously showed that the bone marrow (BM) is a key organ for proliferation and maintenance of both antigen-specific and CD44(high) memory CD8(+) T cells. Interestingly, BM memory CD8(+) T cells express lower levels of membrane CD127 than do the corresponding spleen and lymph node cells. We investigated the requirements for CD127 downmodulation by CD44(high) memory-phenotype CD8(+) T cells in the BM of C57BL/6 mice. By comparing genetically modified (i.e. CD127tg, IL-7 KO, IL-15 KO, IL-15Rα KO) with wild-type (WT) mice, we found that the key molecule regulating CD127 downmodulation was IL-15 but not IL-7, and that the intact CD127 gene was required, including the promoter. Indeed, CD127 mRNA transcript levels were lower in CD44(high) CD8(+) T cells from the BM than in those from the spleen of WT mice, indicating organ-specific regulation. Although levels of the CD127 transactivator Foxo1 were low in BM CD44(high) CD8(+) T cells, Foxo1 was not involved in IL-15-induced CD127 downmodulation. Thus, recirculating CD44(high) CD8(+) T cells passing through the BM transiently downregulate CD127 in response to IL-15, with implications for human therapies acting on the IL-7/CD127 axis, for example cytokine treatments in cancer patients.


Subject(s)
Bone Marrow/immunology , CD8-Positive T-Lymphocytes/immunology , Immunologic Memory , Interleukin-15/immunology , Receptors, Interleukin-7/antagonists & inhibitors , Animals , CD8-Positive T-Lymphocytes/metabolism , Down-Regulation/immunology , Female , Forkhead Box Protein O1 , Forkhead Transcription Factors/analysis , Hyaluronan Receptors/immunology , Mice , Mice, Inbred C57BL , Mice, Transgenic , Promoter Regions, Genetic , Receptors, Interleukin-7/genetics , Receptors, Interleukin-7/immunology , Spleen/immunology
7.
Vaccine ; 29(20): 3708-13, 2011 May 09.
Article in English | MEDLINE | ID: mdl-21406267

ABSTRACT

According to European recommendations, the Italian Medicines Agency (AIFA) required close monitoring of the safety of the MF59-adjuvanted H1N1v vaccine, which was the only vaccine available in Italy for prophylaxis of the A/H1N1 (2009) pandemic influenza. From October 2009 to June 2010, the Italian Pharmacovigilance Adverse Event (AE) Spontaneous Reporting System [Rete Nazionale Farmacovigilanza] (RNF) received 1330 reports of AEs temporally related with the pandemic influenza vaccination out of a total of 924,057 doses administered. Among these, 1,162 (87.37%) AE reports were classified 'non serious', 91 (6.84%) 'serious', 3 (0.23%) had a fatal outcome and 74 (5.56%) did not include the degree of seriousness. Among the serious AE reports, some unexpected AEs emerged. Even though some typical vaccine safety issues which emerged should be further explored, such as vaccination in pregnancy, the analysis of all AE reports sent to RNF shows that the vaccine has a well-tolerated safety profile which resembles that of the already available seasonal influenza vaccines. This contrasts with the widespread public concern about its safety, which has been one of the major causes of the low vaccination rate observed in Italy, as well as in other countries.


Subject(s)
Adverse Drug Reaction Reporting Systems/statistics & numerical data , Influenza Vaccines/adverse effects , Vaccination/adverse effects , Adjuvants, Immunologic/pharmacology , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Humans , Infant , Influenza A Virus, H1N1 Subtype/immunology , Italy , Male , Middle Aged , Polysorbates/pharmacology , Pregnancy , Product Surveillance, Postmarketing , Public Health/statistics & numerical data , Squalene/pharmacology , Vaccination/statistics & numerical data , Young Adult
8.
J Immunol ; 180(11): 7230-9, 2008 Jun 01.
Article in English | MEDLINE | ID: mdl-18490722

ABSTRACT

To study naive and memory CD8 T cell turnover, we performed BrdU incorporation experiments in adult thymectomized C57BL/6 mice and analyzed data in a mathematical framework. The following aspects were novel: 1) we examined the bone marrow, in addition to spleen and lymph nodes, and took into account the sum of cells contained in the three organs; 2) to describe both BrdU-labeling and -delabeling phase, we designed a general mathematical model, in which cell populations were distinguished based on the number of divisions; 3) to find parameters, we used the experimentally determined numbers of total and BrdU(+) cells and the BrdU-labeling coefficient. We treated mice with BrdU continuously via drinking water for up to 42 days, measured by flow cytometry BrdU incorporation at different times, and calculated the numbers of BrdU(+) naive (CD44(int/low)) and memory (CD44(high)) CD8 T cells. By fitting the model to data, we determined proliferation and death rates of both subsets. Rates were confirmed using independent sets of data, including the numbers of BrdU(+) cells at different times after BrdU withdrawal. We found that both doubling time and half-life of the memory population were approximately 9 wk, whereas for the naive subset the doubling time was almost 1 year and the half-life was roughly 7 wk. Our findings suggest that the higher turnover of memory CD8 T cells as compared with naive CD8 T cells is mostly attributable to a higher proliferation rate. Our results have implications for interpreting physiological and abnormal T cell kinetics in humans.


Subject(s)
CD8-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/immunology , Immunologic Memory , T-Lymphocyte Subsets/cytology , T-Lymphocyte Subsets/immunology , Animals , Bone Marrow Cells/cytology , Bromodeoxyuridine/metabolism , CD8-Positive T-Lymphocytes/physiology , Cell Death , Cell Proliferation , Female , Hyaluronan Receptors/metabolism , Kinetics , Lymph Nodes/cytology , Lymphocyte Count , Mathematics , Mice , Mice, Inbred C57BL , Models, Immunological , Spleen/cytology , T-Lymphocyte Subsets/physiology , Thymectomy
9.
Blood ; 110(6): 1960-9, 2007 Sep 15.
Article in English | MEDLINE | ID: mdl-17510323

ABSTRACT

By comparing mature CD8-cell turnover in different organs, we previously demonstrated that CD8 cells proliferate predominantly in the bone marrow (BM). To investigate the mechanisms underlying such increased turnover, we compared BM, lymph nodes, and spleen CD8 cells from untreated C57BL/6 mice regarding in vivo proliferation within the organ; in vitro response to interleukin-7 (IL-7), IL-15, IL-21; ex vivo expression of membrane CD127 (IL-7Ralpha), intracellular Bcl-2, phospho-STAT-5 (signal transducer and activator of transcription 5), phospho-p38 mitogen activated protein kinase (MAPK); and in vivo proliferation on adoptive transfer. In the BM, the proliferation rate was increased for either total CD8 cells or individual CD44 and CD122 subsets. In contrast, purified CD8(+) cells from the BM did not show an enhanced in vitro proliferative response to IL-7, IL-15, and IL-21 compared with corresponding spleen cells. After transfer and polyinosinic-polycytidylic acid (polyI:C) treatment, both spleen-derived and BM-derived CD8 cells from congenic donors proliferated approximately twice more in the recipient BM than in spleen and lymph nodes. Our results suggest that BM CD8 cells are not committed to self-renewal, but rather are stimulated in the organ. Molecular events constantly induced in the CD8 cells within the BM of untreated mice include increase of both phosphorylated STAT-5 and phosphorylated p38 intracellular levels, and the reduction of CD127 membrane expression.


Subject(s)
Bone Marrow/metabolism , CD8 Antigens/metabolism , Cell Membrane , Receptors, Interleukin-7/metabolism , STAT5 Transcription Factor/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism , Adoptive Transfer , Animals , Bone Marrow/growth & development , CD8-Positive T-Lymphocytes , Cell Proliferation/drug effects , Cells, Cultured , Down-Regulation , Immunization , Interleukin-15/pharmacology , Interleukin-7/pharmacology , Interleukins/pharmacology , Lymph Nodes/cytology , Lymph Nodes/metabolism , Mice , Mice, Inbred C57BL , Ovalbumin/administration & dosage , Phosphorylation/drug effects , Receptors, Interleukin-7/genetics , Spleen/cytology , Spleen/metabolism
10.
J Immunol ; 174(12): 7654-64, 2005 Jun 15.
Article in English | MEDLINE | ID: mdl-15944266

ABSTRACT

Long-term persistence of Ag-experienced CD8 cells, a class of T lymphocytes with cytotoxic function, contributes to immunological memory against intracellular pathogens. After Ag clearance, memory CD8 cells are maintained over time by a slow proliferation, primarily cytokine driven. In this article, we show that the bone marrow (BM) is the crucial organ where such basal division of memory CD8 cells occurs. BM memory CD8 cells contain a higher percentage of proliferating cells than their corresponding cells in either spleen or lymph nodes from C57BL/6 mice. This occurs both in the case of memory-phenotype CD44(high) CD8 cells and in the case of Ag-specific memory CD8 cells. Importantly, the absolute number of Ag-specific memory CD8 cells dividing in the BM largely exceeds that in spleen, lymph nodes, liver, and lung taken together. In the BM, Ag-specific memory CD8 cells express lower levels of CD127, i.e., the alpha-chain of IL-7R, than in either spleen or lymph nodes. We interpret these results as indirect evidence that Ag-specific memory CD8 cells receive proliferative signals by IL-7 and/or IL-15 in the BM and propose that the BM acts as a saturable "niche" for the Ag-independent proliferation of memory CD8 cells. Taken together, our novel findings indicate that the BM plays a relevant role in the maintenance of cytotoxic T cell memory, in addition to its previously described involvement in long-term Ab responses.


Subject(s)
Bone Marrow Cells/cytology , Bone Marrow Cells/immunology , CD8-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/immunology , Cell Division/immunology , Cytotoxicity Tests, Immunologic , Immunologic Memory , Adoptive Transfer , Animals , Bone Marrow Cells/metabolism , CD8-Positive T-Lymphocytes/metabolism , Cell Division/genetics , Cell Proliferation , Cell Survival/genetics , Cell Survival/immunology , Cytotoxicity Tests, Immunologic/methods , Epitopes, T-Lymphocyte/immunology , Female , Hyaluronan Receptors/biosynthesis , Immunologic Memory/genetics , Liver/cytology , Liver/immunology , Liver/metabolism , Lung/cytology , Lung/immunology , Lung/metabolism , Lymph Nodes/cytology , Lymph Nodes/immunology , Lymph Nodes/transplantation , Lymphocyte Count , Mice , Mice, Inbred C57BL , Mice, Transgenic , Receptors, Interleukin-7/biosynthesis , Spleen/cytology , Spleen/immunology , Spleen/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...